Researchers this week suggested a GLP-1 receptor agonist may be associated with hair loss, adding a new complaint to the weight loss jabs that include Wegovy and Mounjaro. The signal matters because people using these drugs already face well-documented digestive side-effects, while hair loss is now being raised as a separate concern.
The stronger, established side-effects remain nausea, vomiting, diarrhoea and constipation, which have been documented in clinical trials. GLP-1 medications can slow the progress of food through the digestive tract, slow stomach emptying and affect signalling from the gut to the brain, and manufacturers say those effects usually go away over time.
Wegovy and Mounjaro use
Weight loss jabs such as Wegovy and Mounjaro have boomed in popularity, which has widened attention on what these medicines do beyond appetite control. Last year, a study revealed people with diabetes who use GLP-1 drugs could face double the risk of developing age-related macular degeneration, showing that side-effects under review are not limited to one body system.
Reports based on adverse event reporting systems and matched cohort studies have also suggested some GLP-1 medications have the potential to cause non-arteritic anterior ischaemic optic neuropathy. That condition can cause sudden and permanent sight loss, and pharmaceutical companies accept it is a possible side-effect of some GLP-1 medications. The patient leaflets of Wegovy mention it.
UK Medicines and Healthcare products Regulatory Agency
The UK Medicines and Healthcare products Regulatory Agency has said GLP-1 medicines should not be taken during pregnancy or just before trying to get pregnant. It added: “This is because there is not enough safety data to know whether taking a GLP-1 medicine can cause harm to the baby.” Similar warnings appear in patient information leaflets.
Women using GLP-1 medications have also been encouraged to pair their use with effective contraception. For readers already taking one of these medicines, the practical point is simple: side-effects with clear evidence, such as digestive problems, are already set out in patient information, while the hair loss link remains a newer suggestion that still needs further research.
Reports of hair loss
Hair loss is being discussed alongside facial changes widely reported on social media after rapid weight loss, including sunken eyes, wrinkles, facial ageing and sagging skin. Surgeons recognise those changes as a result of rapid weight loss, and they are not confined to any particular GLP-1 medication.
The same is true for the new hair loss concern. The latest suggestion is about a possible association, not a settled class effect, and the available facts point to a pattern that needs follow-up rather than a finished answer. For people using GLP-1 medicines now, the clearest guidance in the record is to rely on the existing safety warnings while researchers continue to test whether hair loss belongs on the list.
